Development of a histone deacetylase 6 inhibitor and its biological effects

HDAC6 is a microtubule-associated deacetylase

Hubbert, C., Guardiola, A., Shao, R., Kawaguchi, Y., Ito, A., Nixon, A., Yoshida, M., Wang, X.-F., & Yao, T.-P. (2002) · Nature · doi:10.1038/417455a · Cited by 2,403

The Deacetylase HDAC6 Regulates Aggresome Formation and Cell Viability in Response to Misfolded Protein Stress

Kawaguchi, Y., Kovacs, J. J., McLaurin, A. C., Vance, J. M., Ito, A., & Yao, T. (2003) · Cell · doi:10.1016/s0092-8674(03)00939-5 · Cited by 1,529

Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug

Marks, P. A., & Breslow, R. (2007) · Nature Biotechnology · doi:10.1038/nbt1272 · Cited by 1,198

HDAC6 Regulates Hsp90 Acetylation and Chaperone-Dependent Activation of Glucocorticoid Receptor

Kovacs, J. J., Murphy, P. J. M., Gaillard, S., Zhao, X., Wu, J.-T., Nicchitta, C. V., Yoshida, M., Toft, D. O., Pratt, W. B., & Yao, T.-P. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.04.021 · Cited by 1,153

Trehalose, a Novel mTOR-independent Autophagy Enhancer, Accelerates the Clearance of Mutant Huntingtin and α-Synuclein

Sarkar, S., Davies, J. E., Huang, Z., Tunnacliffe, A., & Rubinsztein, D. C. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m609532200 · Cited by 1,142

Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation

Haggarty, S. J., Koeller, K. M., Wong, J. C., Grozinger, C. M., & Schreiber, S. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0430973100 · Cited by 1,066

Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A

Butler, K. V., Kalin, J., Brochier, C., Vistoli, G., Langley, B., & Kozikowski, A. P. (2010) · Journal of the American Chemical Society · doi:10.1021/ja102758v · Cited by 801

HDAC6 controls autophagosome maturation essential for ubiquitin‐selective quality‐control autophagy

Lee, J., Koga, H., Kawaguchi, Y., Tang, W., Wong, E., Gao, Y., Pandey, U. B., Kaushik, S., Tresse, E., Lu, J., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2009.405 · Cited by 756

HDAC6 Modulates Cell Motility by Altering the Acetylation Level of Cortactin

Zhang, X. M., Yuan, Z., Zhang, Y., Yong, S., Salas-Burgos, A., Koomen, J. M., Olashaw, N., Parsons, J. T., Yang, X., Dent, S., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.033 · Cited by 731

Chemical phylogenetics of histone deacetylases

Bradner, J. E., West, N., Grachan, M. L., Greenberg, E. F., Haggarty, S. J., Warnow, T., & Mazitschek, R. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.313 · Cited by 720

Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders

Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564

HDACs and HDAC Inhibitors in Cancer Development and TherapyPreprint

Li, Y., & Seto, E. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026831 · Cited by 1,337

Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials

Lin, A., Giuliano, C. J., Palladino, A. C., John, K. M., Abramowicz, C., Yuan, M. L., Sausville, E. L., Lukow, D. A., Liu, L., Chait, A. R., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw8412 · Cited by 769

Histone deacetylase 6 structure and molecular basis of catalysis and inhibition

Hai, Y., & Christianson, D. W. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2134 · Cited by 521

Inside HDACs with more selective HDAC inhibitors

Roche, J., & Bertrand, P. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.05.047 · Cited by 327

Targeting Metalloenzymes for Therapeutic Intervention

Chen, A. Y., Adamek, R. N., Dick, B. L., Credille, C. V., Morrison, C. N., & Cohen, S. M. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00201 · Cited by 284

HDAC6 as privileged target in drug discovery: A perspective

Pulya, S., Amin, S. A., Adhikari, N., Biswas, S., Jha, T., & Ghosh, B. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105274 · Cited by 274

Targeting histone deacetylases for cancer therapy: Trends and challenges

Liang, T., Wang, F., Elhassan, R. M., Cheng, Y., Tang, X., Chen, W., Fang, H., & Hou, X. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.02.007 · Cited by 222

Histone Deacetylase 6 in Health and Disease

Seidel, C., Schnekenburger, M., Dicato, M. A., & Diederich, M. F. (2015) · Epigenomics · doi:10.2217/epi.14.69 · Cited by 219

Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors

Porter, N. J., Mahendran, A., Breslow, R., & Christianson, D. W. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718823114 · Cited by 190

A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity

Zhang, X., Qin-Ma, Wu, H.-P., Khamis, M. Y., Li, Y., Ma, L., & Liu, H. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01782 · Cited by 160

Recent advances in the discovery of potent and selective HDAC6 inhibitors

Wang, X.-X., Wan, R.-Z., & Liu, Z.-P. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.10.040 · Cited by 152

Next-generation of selective histone deacetylase inhibitors

Yang, F., Zhao, N., Ge, D., & Chen, Y. (2019) · RSC Advances · doi:10.1039/c9ra02985k · Cited by 145

Drugging the HDAC6–HSP90 interplay in malignant cells

Krämer, O. H., Mahboobi, S., & Sellmer, A. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.08.001 · Cited by 133

Strategies To Design Selective Histone Deacetylase Inhibitors

Melesina, J., Simoben, C. V., Praetorius, L., Bülbül, E. F., Robaa, D., & Sippl, W. (2021) · ChemMedChem · doi:10.1002/cmdc.202000934 · Cited by 118

Histone Deacetylase 6-Selective Inhibitors and the Influence of Capping Groups on Hydroxamate-Zinc Denticity

Porter, N. J., Osko, J. D., Diedrich, D., Kurz, T., Hooker, J. M., Hansen, F. K., & Christianson, D. W. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01013 · Cited by 111

Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer

Yang, Z., Wang, T., Wang, F., Niu, T., Liu, Z., Chen, X. L., Long, C., Tang, M., Cao, D., Wang, X., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01342 · Cited by 111

Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors

Vögerl, K., Ong, N., Senger, J., Herp, D., Schmidtkunz, K., Marek, M., Müller, M., Bartel, K., Shaik, T. B., Porter, N. J., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01090 · Cited by 104

A patent review of IDO1 inhibitors for cancer

Cheong, J. E., Ekkati, A. R., & Sun, L. (2018) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2018.1441290 · Cited by 104

Histone Deacetylase 6 Inhibits Influenza A Virus Release by Downregulating the Trafficking of Viral Components to the Plasma Membrane via Its Substrate, Acetylated Microtubules

Husain, M., & Cheung, C. (2014) · Journal of Virology · doi:10.1128/jvi.00727-14 · Cited by 100

HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors

Sangwan, R., Rajan, R., & Mandal, P. K. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.08.073 · Cited by 97

Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated

Géraldy, M. N. E., Morgen, M., Sehr, P. A., Steimbach, R. R., Moi, D., Ridinger, J., Oehme, I., Witt, O., Malz, M., Nogueira, M. S., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01936 · Cited by 96

The Role of KLF2 in the Regulation of Atherosclerosis Development and Potential Use of KLF2-Targeted Therapy

Dabravolski, S. A., Sukhorukov, V. N., Kalmykov, V. A., Grechko, A. V., Shakhpazyan, N. K., & Orekhov, A. N. (2022) · Biomedicines · doi:10.3390/biomedicines10020254 · Cited by 96

HDAC6: A unique HDAC family member as a cancer target

Kaur, S., Rajoria, P., & Chopra, M. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00704-6 · Cited by 97

How Does Chirality Determine the Selective Inhibition of Histone Deacetylase 6? A Lesson from Trichostatin A Enantiomers Based on Molecular Dynamics

Zhang, Y., Ying, J. B., Hong, J. J., Li, F., Fu, T. T., Yang, F. Y., Zheng, G. X., Yao, X., Lou, Y., Qiu, Y., et al. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00729 · Cited by 95

Epigenetic modulators as therapeutic targets in prostate cancer

Graça, I. C. R., Pereira-Silva, E., Henrique, R., Packham, G., Crabb, S. J., & Jerónimo, C. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0264-8 · Cited by 90

Squaramides as Bioisosteres in Contemporary Drug Design

Agnew‐Francis, K. A., & Williams, C. M. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00416 · Cited by 88

Small Molecules Targeting HATs, HDACs, and BRDs in Cancer Therapy

Wu, D., Qiu, Y., Jiao, Y., Qiu, Z., & Liu, D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.560487 · Cited by 84

A quorum-sensing signal promotes host tolerance training through HDAC1-mediated epigenetic reprogramming

Bandyopadhaya, A., Tsurumi, A., Maura, D., Jeffrey, K. L., & Rahme, L. G. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.174 · Cited by 82

Photoorganocatalytic One‐Pot Synthesis of Hydroxamic Acids from Aldehydes

Papadopoulos, G. N., & Kokotos, C. G. (2016) · Chemistry - A European Journal · doi:10.1002/chem.201600333 · Cited by 78

HDAC Family Members Intertwined in the Regulation of Autophagy: A Druggable Vulnerability in Aggressive Tumor Entities

Koeneke, E., Witt, O., & Oehme, I. (2015) · Cells · doi:10.3390/cells4020135 · Cited by 76

Therapeutic effect of a novel histone deacetylase 6 inhibitor, CKD-L, on collagen-induced arthritis in vivo and regulatory T cells in rheumatoid arthritis in vitro

Oh, B. R., Suh, D., Bae, D., Ha, N., Choi, Y. I., Yoo, H. J., Park, J. K., Lee, E. Y., Lee, E. B., & Song, Y. W. (2017) · Arthritis Research & Therapy · doi:10.1186/s13075-017-1357-2 · Cited by 72

Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease

Rabal, O., Sánchez-Arias, J. A., Cuadrado‐Tejedor, M., de Miguel, I., Pérez-González, M., García, C., Ugarte, A., de Mendoza, A. E., Sáez, E., Espelosin, M., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.03.005 · Cited by 71

Entropy as a Driver of Selectivity for Inhibitor Binding to Histone Deacetylase 6

Porter, N. J., Wagner, F. F., & Christianson, D. W. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00367 · Cited by 64

Phase separation of phospho-HDAC6 drives aberrant chromatin architecture in triple-negative breast cancer

Lu, B., Qiu, R., Wei, J., Wang, L., Zhang, Q., Li, M., Zhan, X., Chen, J., Hsieh, I.-Y., Yang, C., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00816-y · Cited by 65

4-Hydroxybenzoic acid derivatives as HDAC6-specific inhibitors modulating microtubular structure and HSP90α chaperone activity against prostate cancer

Seidel, C., Schnekenburger, M., Mazumder, A., Teiten, M.-H., Kirsch, G., Dicato, M. A., & Diederich, M. F. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.11.005 · Cited by 62

Identification of a Novel Aminotetralin Class of HDAC6 and HDAC8 Selective Inhibitors

Tang, G., Wong, J. C., Zhang, W., Wang, Z., Zhang, N., Peng, Z., Zhang, Z., Rong, Y., Li, S., Zhang, M., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5008962 · Cited by 62

Design, synthesis and evaluate of novel dual FGFR1 and HDAC inhibitors bearing an indazole scaffold

Liu, J., Qian, C., Zhu, Y., Cai, J., He, Y., Li, J., Wang, T., Zhu, H., Li, Z., Li, W., et al. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.12.041 · Cited by 61

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma

Phimmachanh, M., Han, J. Z. R., O’Donnell, Y. E. I., Latham, S. L., & Croucher, D. R. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.578770 · Cited by 61

Epigenetic modifications as regulatory elements of autophagy in cancer

Sui, X., Zhu, J., Zhou, J., Wang, X., Li, D., Han, W., Fang, Y., & Pan, H. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.02.009 · Cited by 57

Valproic acid attenuates sepsis-induced myocardial dysfunction in rats by accelerating autophagy through the PTEN/AKT/mTOR pathway

Shi, X., Liu, Y., Zhang, D., & Xiao, D. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116613 · Cited by 58

Novel Benzohydroxamate-Based Potent and Selective Histone Deacetylase 6 (HDAC6) Inhibitors Bearing a Pentaheterocyclic Scaffold: Design, Synthesis, and Biological Evaluation

Vergani, B., Sandrone, G., Marchini, M., Ripamonti, C., Cellupica, E., Galbiati, E., Caprini, G., Pavich, G., Porro, G., Rocchio, I., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01194 · Cited by 56

Synthesis and applications of benzohydroxamic acid-based histone deacetylase inhibitors

Vreese, R. D., & D’hooghe, M. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.013 · Cited by 55

HDAC6 regulates microtubule stability and clustering of AChRs at neuromuscular junctions

Osseni, A., Ravel‐Chapuis, A., Thomas, J.-L., Gache, V., Schaeffer, L., & Jasmin, B. J. (2020) · The Journal of Cell Biology · doi:10.1083/jcb.201901099 · Cited by 55

Novel 2, 5-diketopiperazine derivatives as potent selective histone deacetylase 6 inhibitors: Rational design, synthesis and antiproliferative activity

Chen, X., Chen, X., Steimbach, R. R., Wu, T., Li, H., Dan, W., Shi, P., Cao, C., Li, D., Miller, A. K., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111950 · Cited by 54

Rational design and diversity-oriented synthesis of peptoid-based selective HDAC6 inhibitors

Diedrich, D., Hamacher, A., Gertzen, C. G. W., Avelar, L. A. A., Reiß, G. J., Kurz, T., Gohlke, H., Kassack, M. U., & Hansen, F. K. (2016) · Chemical Communications · doi:10.1039/c5cc10301k · Cited by 52

Alkoxyurea-Based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines

Stenzel, K., Hamacher, A., Hansen, F. K., Gertzen, C. G. W., Senger, J., Marquardt, V., Marek, L., Marek, M., Romier, C., Remke, M., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01538 · Cited by 51

The HDAC6 inhibitor C1A modulates autophagy substrates in diverse cancer cells and induces cell death

Kaliszczak, M. A., van Hechanova, E., Li, Y., Al-Sadah, H. A., Parzych, K., Auner, H. W., & Aboagye, E. O. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0232-5 · Cited by 51

The emerging potential of autophagy-based therapies in the treatment of cystic fibrosis lung infections

Junkins, R. D., McCormick, C., & Lin, T. (2014) · Autophagy · doi:10.4161/auto.27750 · Cited by 51

HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinoma

Ramakrishnan, S., Ku, S., Ciamporcero, E. S., Miles, K. M., Attwood, K. M., Chintala, S., Shen, L., Ellis, L., Sotomayor, P. C., Swetzig, W. M., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2604-7 · Cited by 50

Anti-cancer effects of naturally derived compounds targeting histone deacetylase 6-related pathways

Lernoux, M., Schnekenburger, M., Dicato, M. A., & Diederich, M. F. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.11.004 · Cited by 49

Inhibition of glioblastoma cell proliferation, invasion, and mechanism of action of a novel hydroxamic acid hybrid molecule

Zhang, I., Beus, M., Stochaj, U., Le, P. U., Zorc, B., Rajić, Z., Petrecca, K., & Maysinger, D. (2018) · Cell Death Discovery · doi:10.1038/s41420-018-0103-0 · Cited by 48

Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells

Rosik, L., Niegisch, G., Fischer, U., Jung, M., Schulz, W. A., & Hoffmann, M. J. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.28469 · Cited by 47

Dual inhibitors of HDAC and other epigenetic regulators: A novel strategy for cancer treatment

Shirbhate, E., Singh, V. P., Jahoriya, V., Mishra, A., Veerasamy, R., Tiwari, A. K., & Rajak, H. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115938 · Cited by 47

Small molecules targeting HDAC6 for cancer treatment: Current progress and novel strategies

Huang, Z., Li, L., Cheng, B., & Li, D. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117218 · Cited by 46

Advice on assistance and protection provided by the Scientific Advisory Board of the Organisation for the Prohibition of Chemical Weapons: Part 1. On medical care and treatment of injuries from nerve agents

Timperley, C. M., Forman, J. E., Abdollahi, M. R., Al-Amri, A. S., Baulig, A., Benachour, D., Borrett, V. T., Cariño, F. A., Geist, M., González, D., et al. (2019) · Toxicology · doi:10.1016/j.tox.2019.01.004 · Cited by 45

Design and Synthesis of Orally Bioavailable Aminopyrrolidinone Histone Deacetylase 6 Inhibitors

Lin, X., Chen, W.-M., Qiu, Z., Guo, L., Zhu, W., Li, W., Wang, Z., Zhang, W., Zhang, Z., Rong, Y., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm502011f · Cited by 44

Histone deacetylase 6 inhibitor ACY-1215 protects against experimental acute liver failure by regulating the TLR4-MAPK/NF-κB pathway

Zhang, W., Zhang, H., Jiao, F., Wang, L.-W., Zhang, H., & Gong, Z. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.10.103 · Cited by 44

Differential molecular mechanistic behavior of HDACs in cancer progression

Singh, T., Kaur, P., Singh, P., Singh, S., & Munshi, A. (2022) · Medical Oncology · doi:10.1007/s12032-022-01770-4 · Cited by 42

Methods for Hydroxamic Acid Synthesis

Alam, M. A. (2019) · Current Organic Chemistry · doi:10.2174/1385272823666190424142821 · Cited by 41

Development and pre-clinical testing of a novel hypoxia-activated KDAC inhibitor

Skwarska, A., Calder, E. D. D., Sneddon, D., Bolland, H. R., Odyniec, M. L., Mistry, I. N., Martin, J., Folkes, L. K., Conway, S. J., & Hammond, E. M. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.04.004 · Cited by 38

Synthesis of Potent and Selective HDAC6 Inhibitors Bearing a Cyclohexane‐ or Cycloheptane‐Annulated 1,5‐Benzothiazepine Scaffold

Vreese, R. D., Galle, L. M., Depetter, Y., Franceus, J., Desmet, T., Hecke, K. V., Benoy, V., Bosch, L. V. D., & D’hooghe, M. (2016) · Chemistry - A European Journal · doi:10.1002/chem.201604167 · Cited by 38

Creation of a histone deacetylase 6 inhibitor and its biological effects

Lee, J., Yao, Y., Mahendran, A., Ngo, L., Venta-Perez, G., Choy, M. L., Breslow, R., & Marks, P. A. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1515882112 · Cited by 37

Inhibition of histone deacetylase 6 suppresses inflammatory responses and invasiveness of fibroblast-like-synoviocytes in inflammatory arthritis

Park, J. K., Shon, S. H., Yoo, H. J., Suh, D., Bae, D., Shin, J., Jun, J. H., Ha, N., Song, H., Choi, Y. I., et al. (2021) · Arthritis Research & Therapy · doi:10.1186/s13075-021-02561-4 · Cited by 35

HPOB, an HDAC6 inhibitor, attenuates corticosterone-induced injury in rat adrenal pheochromocytoma PC12 cells by inhibiting mitochondrial GR translocation and the intrinsic apoptosis pathway

Li, Z., Li, Q., Chen, L., Chen, B.-D., Zhang, C., Wang, X., & Li, W. (2016) · Neurochemistry International · doi:10.1016/j.neuint.2016.08.004 · Cited by 35

Recent advancement of HDAC inhibitors against breast cancer

Mehmood, S. A., Sahu, K. K., Sengupta, S., Partap, S., Karpoormath, R. V., Kumar, B., & Kumar, D. (2023) · Medical Oncology · doi:10.1007/s12032-023-02058-x · Cited by 34

Synthesis of benzothiophene-based hydroxamic acids as potent and selective HDAC6 inhibitors

Vreese, R. D., Steen, N. V., Verhaeghe, T., Desmet, T., Bougarne, N., Bosscher, K. D., Benoy, V., Haeck, W., Bosch, L. V. D., & D’hooghe, M. (2015) · Chemical Communications · doi:10.1039/c5cc03295d · Cited by 32

Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs

Wang, Y., Wallach, J. V., Duane, S., Wang, Y., Wu, J., Wang, J., Adejare, A., & Ma, H. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s124977 · Cited by 32

HDAC6—An Emerging Target Against Chronic Myeloid Leukemia?

Losson, H., Schnekenburger, M., Dicato, M. A., & Diederich, M. F. (2020) · Cancers · doi:10.3390/cancers12020318 · Cited by 36

Identification of novel 1,3-diaryl-1,2,4-triazole-capped histone deacetylase 6 inhibitors with potential anti-gastric cancer activity

Zhang, X., Kang, H., Tao, Y., Li, Y., Zhao, J., Ya-Gao, Ma, L., & Liu, H. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113392 · Cited by 31

In silico design of novel benzohydroxamate-based compounds as inhibitors of histone deacetylase 6 based on 3D-QSAR, molecular docking, and molecular dynamics simulations

Chu, H., He, Q., Wang, J., Hu, Y. Q., Wang, Y., & Lin, Z. (2020) · New Journal of Chemistry · doi:10.1039/d0nj04704j · Cited by 30

Dual LSD1 and HDAC6 Inhibition Induces Doxorubicin Sensitivity in Acute Myeloid Leukemia Cells

Bulut, İ., Lee, A. F., Cevatemre, B., Ružić, D., Belle, R., Kawamura, A., Gul, S., Nikolic, K. M., Ganesan, A., & Açılan, C. (2022) · Cancers · doi:10.3390/cancers14236014 · Cited by 29

An Overview of HDAC Inhibitors and their Synthetic Routes

Peng, X., Liao, G., Sun, P., Yu, Z., & Chen, J. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190227221507 · Cited by 28

Tetrahydro-β-carboline derivatives as potent histone deacetylase 6 inhibitors with broad-spectrum antiproliferative activity

Chen, X., Wang, J., Zhao, P., Dang, B., Liang, T., Steimbach, R. R., Miller, A. K., Liu, J., Wang, X., Zhang, T., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115776 · Cited by 26

SKLB-23bb, A HDAC6-Selective Inhibitor, Exhibits Superior and Broad-Spectrum Antitumor Activity via Additionally Targeting Microtubules

Wang, F., Zheng, L., Yi, Y., Yang, Z., Qiu, Q., Wang, X., Yan, W., Bai, P., Yang, J., Li, D., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0332 · Cited by 27

HDAC6 inhibition: a significant potential regulator and therapeutic option to translate into clinical practice in renal transplantation

Zhang, Q.-Q., Zhang, W.-J., & Chang, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1168848 · Cited by 24

CKD-506: A novel HDAC6-selective inhibitor that exerts therapeutic effects in a rodent model of multiple sclerosis

Bae, D., Lee, J., Ha, N., Park, J., Baek, J., Suh, D., Lim, H. S., Ko, S. M., Kim, T., Jeong, D. S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-93232-6 · Cited by 24

Highly fluorescent and HDAC6 selective scriptaid analogues

Fleming, C. L., Natoli, A. L., Schreuders, J., Devlin, M. G., Yoganantharajah, P., Gibert, Y., Leslie, K. G., New, E. J., Ashton, T. D., & Pfeffer, F. M. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.11.020 · Cited by 24

Structural and energetic basis for the inhibitory selectivity of both catalytic domains of dimeric HDAC6

Sixto‐López, Y., Bello, M., & Correa‐Basurto, J. (2018) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2018.1557560 · Cited by 23

Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor

Soumyanarayanan, U., Ramanujulu, P. M., Mustafa, N. B., Haider, S. M., Nee, A. H. F., Tong, J. X., Tan, K. S. W., Chng, W. J., & Dymock, B. W. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111755 · Cited by 23

Overexpression of HDAC6, but not HDAC3 and HDAC4 in the penumbra after photothrombotic stroke in the rat cerebral cortex and the neuroprotective effects of α-phenyl tropolone, HPOB, and sodium valproate

Demyanenko, S. V., Dzreyan, V., & Uzdensky, A. B. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.06.010 · Cited by 23

Vorinostat-eluting poly(DL-lactide-co-glycolide) nanofiber-coated stent for inhibition of cholangiocarcinoma cells

Kwak, T. W., Lee, H. L., Song, Y. H., Kim, C., Kim, J., Seo, S.-J., Jeong, Y., & Kang, D. H. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s141920 · Cited by 23

Analysis of class I and II histone deacetylase gene expression in human leukemia

Yang, H., Maddipoti, S., Quesada, A. E., Bohannan, Z. S., Cabrero, M., Colla, S., Wei, Y., Estecio, M. R., Wierda, W. G., Bueso-Ramos, C., et al. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1034705 · Cited by 22

Phenylpyrrole-Based Hdac Inhibitors: Synthesis, Molecular Modeling and Biological Studies

Brindisi, M., Cavella, C., Brogi, S., Nebbioso, A., Senger, J., Maramai, S., Ciotta, A., Iside, C., Butini, S., Lamponi, S., et al. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0068 · Cited by 22

Histone deacetylase 6 plays an important role in TGF-β-induced murine Treg cell differentiation by regulating cell proliferation

Lee, J. H., Kim, H. S., Jang, S. W., & Lee, G. R. (2022) · Scientific Reports · doi:10.1038/s41598-022-27230-7 · Cited by 22

Combined Ligand and Fragment‐based Drug Design of Selective Histone Deacetylase – 6 Inhibitors

Ružić, D., Petković, M., Agbaba, D. D., Ganesan, A., & Nikolic, K. M. (2019) · Molecular Informatics · doi:10.1002/minf.201800083 · Cited by 21

Recent Advances in Small Molecular Modulators Targeting Histone Deacetylase 6

Xiao, Y., & Zhang, X. (2020) · Future Drug Discovery · doi:10.4155/fdd-2020-0023 · Cited by 20

Advice on assistance and protection provided by the Scientific Advisory Board of the Organisation for the Prohibition of Chemical Weapons: Part 3. On medical care and treatment of injuries from sulfur mustard

Timperley, C. M., Forman, J. E., Abdollahi, M. R., Al-Amri, A. S., Baulig, A., Benachour, D., Borrett, V. T., Cariño, F. A., Curty, C., Geist, M., et al. (2021) · Toxicology · doi:10.1016/j.tox.2021.152967 · Cited by 19

Histone deacetylase 6 inhibitors with blood-brain barrier penetration as a potential strategy for CNS-Disorders therapy

Gu, X. Q., Zhang, H., Jiao, M.-R., Han, B. R., Zhang, Z., Li, J., & Zhang, Q. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114090 · Cited by 18

Genetic deletion of the H istone D eacetylase 6 exacerbates selected behavioral deficits in the R6/1 mouse model for Huntington's disease

Ragot, A., Pietropaolo, S., Vincent, J. D., Delage, P., Zhang, H., Allinquant, B., Leinekugel, X., Fischer, A., & Cho, Y. H. (2015) · Brain and Behavior · doi:10.1002/brb3.361 · Cited by 21

Binding Free Energy (BFE) Calculations and Quantitative Structure–Activity Relationship (QSAR) Analysis of Schistosoma mansoni Histone Deacetylase 8 (smHDAC8) Inhibitors

Simoben, C. V., Ghazy, E., Zeyen, P., Darwish, S., Schmidt, M., Romier, C., Robaa, D., & Sippl, W. (2021) · Molecules · doi:10.3390/molecules26092584 · Cited by 17

Rescue of CFTR NBD2 mutants N1303K and S1235R is influenced by the functioning of the autophagosome

Liu, Q., Sabirzhanova, I. B., Yanda, M. K., Bergbower, E. A. S., Boinot, C., Guggino, W. B., & Cebotaru, L. (2018) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2018.05.016 · Cited by 16

The Co-Expression Pattern of p63 and HDAC1: A Potential Way to Disclose Stem Cells in Interfollicular Epidermis

Shin, J.-W., Choi, H., Nam, K.-M., Lee, H.-S., Kim, S.-A., Joe, H.-J., Toyama, K., & Park, K. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071360 · Cited by 14

A novel action mechanism for MPT0G013, a derivative of arylsulfonamide, inhibits tumor angiogenesis through up-regulation of TIMP3 expression

Wang, C.-Y., Liou, J., Tsai, A.-C., Lai, M.-J., Liu, Y., Lee, H., Wang, J.-C., Pan, S., & Teng, C. (2014) · Oncotarget · doi:10.18632/oncotarget.2451 · Cited by 14

The Role of HDAC6 in Glioblastoma Multiforme: A New Avenue to Therapeutic Interventions?

Spallotta, F., & Illi, B. (2024) · Biomedicines · doi:10.3390/biomedicines12112631 · Cited by 13

Overcome the tumor immunotherapy resistance by combination of the HDAC6 inhibitors with antitumor immunomodulatory agents

Khamis, M. Y., Wu, H.-P., Ma, Q., Li, Y., Ma, L., Zhang, X., & Liu, H. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104754 · Cited by 12

Insecticidal activities of histone deacetylase inhibitors against a dipteran parasite of sheep, Lucilia cuprina

Bagnall, N. H., Hines, B. M., Lucke, A. J., Gupta, P. K., Reid, R. C., Fairlie, D. P., & Kotze, A. C. (2017) · International Journal for Parasitology Drugs and Drug Resistance · doi:10.1016/j.ijpddr.2017.01.001 · Cited by 12

Pharmacophore-based virtual screening of ZINC database, molecular modeling and designing new derivatives as potential HDAC6 inhibitors

Poonia, P., Sharma, M., Jha, P. K., & Chopra, M. (2022) · Molecular Diversity · doi:10.1007/s11030-022-10540-3 · Cited by 11

Identification of HDAC6 selective inhibitors: pharmacophore based virtual screening, molecular docking and molecular dynamics simulation

Yan, G., Li, D., Zhong, X.-X., Liu, G., Wang, X., Lu, Y., Qin, F., Guo, Y., Duan, S., & Li, D. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1743760 · Cited by 11

Screening of an Epigenetic Drug Library Identifies 4-((hydroxyamino)carbonyl)-N-(2-hydroxyethyl)-N-Phenyl-Benzeneacetamide that Reduces Melanin Synthesis by Inhibiting Tyrosinase Activity Independently of Epigenetic Mechanisms

Song, H., Hwang, Y. J., Ha, J. W., & Boo, Y. C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134589 · Cited by 11

Creation of a histone deacetylase 6 inhibitor and its biological effects

Lee, J., Yao, Y., Mahendran, A., Ngo, L., Venta-Perez, G., Choy, M. L., Breslow, R., & Marks, P. A. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1515882112 · Cited by 37

Abstract LB-308: Development of histone deacetylase 6 inhibitors: Effects of HDAC6 inhibitors in normal and cancer cells.

Lee, J., Choy, M. L., Ngo, L., Venta-Perez, G., Mahendran, A., Yao, Y., Breslow, R., & Marks, P. A. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-lb-308

Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 selective inhibitors bearing phenylpyrazol scaffold as surface recognition motif

Yang, J., Cheng, G., Xu, Q., Luan, S., Wang, S., Liu, D., & Zhao, L. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.08.029 · Cited by 25

The principal pivot : new potent HDAC6 selective inhibitors with a non-hydroxamic acid zinc binding group for applications beyond oncology

Geurs, S. (2022) · Ghent University Academic Bibliography (Ghent University)

Preferential HDAC6 inhibitors derived from HPOB exhibit synergistic antileukemia activity in combination with decitabine

Tretbar, M., Schliehe‐Diecks, J., von Bredow, L., Tan, K., Roatsch, M., Tu, J., Kemkes, M., Sönnichsen, M., Schöler, A., Borkhardt, A., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116447 · Cited by 11